Article Details
Retrieved on: 2025-05-20 20:06:14
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the FDA's new risk-based approval framework for COVID-19 vaccines, specifically targeting high-risk populations and aligning with the recent approval of Novavax's updated vaccine. It emphasizes restoring public trust and reducing perpetual booster cycles.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here